Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EB005

            Therapeutic Area: Dermatology Product Name: EB005

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: $224.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 11, 2021

            Details:

            Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.